COVID-19 will continue to be a major problem for organisers in 2021. Various industry and trade shows have already been cancelled or postponed, as reported by the Association of the German Trade Fair Industry (AUMA). The new mutations of the virus give rise to further uncertainties for future developments. Travel restrictions and quarantine regulations further contribute to planning uncertainty.
 
Therefore, the board of SEPAWA® e.V. has decided to hold the SEPAWA® CONGRESS 2021 exclusively on a virtual basis.
 
"This decision has been very difficult for us. However, we want to give our exhibitors and participants planning security. We definitely want to avoid a last-minute cancellation like we had to do in 2020. This would mean unnecessary costs and time lost for everyone involved. The health of our visitors and participants is always paramount, and at the moment we cannot predict with certainty the development of the pandemic, the vaccination status, or any hygiene regulations and participant restrictions in the autumn. Therefore, we think that the virtual option is the only right one. We hope that the current decision is in the interest of all participating companies and delegates,"
- Dr. Hans Jürgen Scholz, 1st Chairman

Meet your business from wherever you are!

The experience with a virtual event in 2020 was very positive. The platform was consistently rated positively by the participants. In the meantime, the system has been continuously improved by the manufacturer and provided with new functions. Above all, the virtual exhibition area has undergone decisive innovations.
 
"We are convinced that the virtual SEPAWA® CONGRESS 2021 will be successful. By committing to a digital event early on, there is enough time to prepare thoroughly for participation," explains Robert Fischer, SEPAWA® press officer.
 
Take the opportunity to present your latest scientific research results at SEPAWA® CONGRESS VIRTUAL 2021.
 
Zrzut ekranu 2021 02 18 o 14.16.47

Contact
Nancy Snehotta
Mail: nancy.snehotta@sofw.com
 
SEPAWA Logo medQ2
Back to top